Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Radiology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pathol Res Pract. 2024 Oct;262:155547. doi: 10.1016/j.prp.2024.155547. Epub 2024 Aug 15.
Late diagnosis is considered one of the main reasons of high mortality rate among cancer patients that results in therapeutic failure and tumor relapse. Therefore, it is needed to evaluate the molecular mechanisms associated with tumor progression to introduce efficient markers for the early tumor detection among cancer patients. The remarkable stability of microRNAs (miRNAs) in body fluids makes them potential candidates to use as the non-invasive tumor biomarkers in cancer screening programs. MiR-135b has key roles in prognosis and survival of cancer patients by either stimulating or inhibiting cell proliferation, invasion, and angiogenesis. Therefore, in the present review we assessed the molecular biology of miR-135b during tumor progression to introduce that as a novel tumor marker in cancer patients. It has been reported that miR-135b mainly acts as an oncogene by regulation of transcription factors, signaling pathways, drug response, cellular metabolism, and autophagy. This review paves the way to suggest miR-135b as a tumor marker and therapeutic target in cancer patients following the further clinical trials and animal studies.
晚期诊断被认为是癌症患者死亡率高的主要原因之一，导致治疗失败和肿瘤复发。因此，有必要评估与肿瘤进展相关的分子机制，以引入有效的肿瘤标志物用于癌症患者的早期肿瘤检测。miRNAs（microRNAs）在体液中具有显著的稳定性，使其成为癌症筛查计划中作为非侵入性肿瘤生物标志物的潜在候选物。miR-135b 通过刺激或抑制细胞增殖、侵袭和血管生成，在癌症患者的预后和生存中发挥关键作用。因此，在本综述中，我们评估了 miR-135b 在肿瘤进展过程中的分子生物学，以将其作为癌症患者的新型肿瘤标志物进行介绍。据报道，miR-135b 主要通过调节转录因子、信号通路、药物反应、细胞代谢和自噬来作为致癌基因发挥作用。在进一步的临床试验和动物研究之后，本综述为将 miR-135b 作为肿瘤标志物和治疗靶点提供了依据。
